Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem?

Related Experiment Video

Updated: Jul 15, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Eve A Roberts1

  • 1Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. eve.roberts@sickkids.ca

Journal of Hepatology
|April 21, 2007
PubMed

Insights

Pediatric nonalcoholic fatty liver disease (NAFLD) is rising with childhood obesity. Understanding its unique mechanisms in children is key to developing effective prevention and treatment strategies for liver health.

Area of Science:

  • Hepatology
  • Pediatrics
  • Metabolic Disorders

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is increasingly diagnosed in children, coinciding with the global pediatric obesity epidemic.
  • Pediatric NAFLD exhibits distinct characteristics compared to adult NAFLD, potentially due to metabolic changes during critical growth phases.
  • The long-term outcomes of pediatric NAFLD are unknown, but progression to cirrhosis is possible.

Purpose of the Study:

  • To investigate the unique pathogenesis of nonalcoholic fatty liver disease in children.
  • To explore the role of hepatic metabolic derangements during childhood growth periods in NAFLD development.
  • To identify potential therapeutic targets and prevention strategies for pediatric NAFLD.

Main Methods:

  • This study reviews current literature on pediatric NAFLD.
  • It analyzes the differences between adult and pediatric NAFLD.
  • It discusses the role of hyperinsulinemia and insulin resistance in pediatric NAFLD pathogenesis.

Main Results:

  • Hyperinsulinemia and insulin resistance are identified as critical factors in the development of pediatric NAFLD.
  • Hepatic metabolic derangements during infancy, mid-childhood, and puberty may contribute to NAFLD differences in children.
  • The natural history and specific mechanisms of pediatric NAFLD require further investigation.

Conclusions:

  • Understanding the pathogenesis of pediatric NAFLD is crucial for advancing knowledge across all age groups.
  • Identifying novel treatment opportunities for NAFLD in children is a significant public health goal.
  • Developing effective prevention strategies for pediatric NAFLD is essential for improving children's long-term health outcomes.

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...